Viking Therapeutics (VKTX) Posts Q2 Loss of $1.07/Share

Viking Therapeutics (NASDAQ: VKTX) reported Q2 EPS of ($1.07), $0.94 worse than the analyst estimate of ($0.13).

The decrease in net loss and net loss per share in the three months ended June 30, 2015 was primarily due to the company recording a $21.2 million estimated license fee liability during the three months ended June 30, 2014 which it did not record during the three months ended June 30, 2015, as well as additional shares outstanding following the company's recent initial public offering of common stock. The decrease in net loss was partially offset by the company's recording of approximately $3.5 million in incremental non-cash other expense in the three months ended June 30, 2015 related to increases in the fair value of the license fee liability.

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• United Airlines maintains forecast after Q1 results top Wall Street estimates
• Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
• Interactive Brokers (IBKR) Tops Q1 EPS by 2c